The Agrobacterium tumefaciens virB7 gene product is a lipoprotein whose function is required for the transmission of oncogenic T-DNA to susceptible plant cells. Three lines of study provided evidence that VirB7 interacts with and stabilizes other VirB proteins during the assembly of the putative T-complex transport apparatus. First, a precise deletion of virB7 from the pTiA6NC plasmid of wild-type strain A348 was correlated with significant reductions in the steady-state levels of several VirB proteins, including VirB4, VirB9, VirB10, and VirB11; trans expression of virB7 in the ⌬virB7 mutant partially restored the levels of these proteins, and trans coexpression of virB7 and virB8 fully restored the levels of these proteins to wild-type levels. Second, modulation of VirB7 levels resulted in corresponding changes in the levels of other VirB proteins in the following cell types: (i) a ⌬virB7 mutant expressing virB7 and virB8 from isopropyl-␤-D-thiogalactopyranoside (IPTG)-inducible P lac and other virB genes from acetosyringone (AS)-inducible P virB ; (ii) a ⌬virB operon mutant expressing virB7 and virB8 from P lac and virB9, virB10, and virB11 from P virB ; and (iii) a ⌬virB operon mutant expressing virB7 from IPTG-inducible P lac and virB9 from an AS-inducible P virB . Third, the synthesis of a VirB7::PhoA fusion protein in strain A348 was correlated with a significant reduction in the steady-state levels of VirB4, VirB5, and VirB7 through VirB11; these cells also exhibited a severely attenuated virulence phenotype, indicating that synthesis of the fusion protein perturbs the assembly of VirB proteins into a stabilized protein complex required for T-complex transport. Extracts of AS-induced cells electrophoresed under nonreducing conditions possessed undetectable levels of the 32-kDa VirB9 and 4.5-kDa VirB7 monomers and instead possessed a 36-kDa complex that cross-reacted with both VirB7 and VirB9 antisera and accumulated as a function of virB7 expression. Our results are consistent with a model in which VirB7 stabilizes VirB9 by formation of a covalent intermolecular cross-link; in turn, the VirB7-VirB9 heterodimer promotes the assembly of a functional T-complex transport machinery.
The Agrobacterium tumefaciens ϳ9.5-kb virB operon encodes 11 proteins which are proposed to assemble into a transport apparatus required for the transmission of a complex of DNA and protein (T-complexes) to susceptible plant cells (for recent reviews, see references 11, 23, 26, 50, and 51) . Recent genetic analyses have demonstrated that the products of virB2 through virB11 are essential for this transport process whereas the product of virB1 serves to enhance the efficiency of nucleoprotein transfer (6) .
Considerable efforts in several laboratories are being directed toward a structural definition of the putative virB-encoded T-complex transport apparatus. Initial studies have focused on defining the subcellular localizations and topologies of the VirB proteins. DNA sequence analyses of the virB operon showed that most of the VirB proteins contain signal sequences or hydrophobic domains suggestive of an association with or export across the cytoplasmic membrane (24, 38, 42, 45, 46) . Several lines of investigation have provided experimental confirmation that VirB proteins associate with the A. tumefaciens envelope. (i) Subcellular localization studies have shown that each of the 10 VirB proteins examined thus far associates with the cytoplasmic or outer membrane or both (5, 9, 15, 16, 37, 41, 43, 48) . (ii) Analyses of fusions between the virB genes and phoA, an Escherichia coli gene encoding periplasmically active alkaline phosphatase, provided evidence that each of the VirB proteins except for VirB11 possesses an exported domain (4, 9, 12, 15, 48) . (iii) A combination of virB::phoA analyses and protease susceptibility studies provided evidence that several of the VirB proteins, including VirB5 and VirB7 through VirB10, possess large periplasmic domains (12, 15, 48) . (iv) Immunolocalization studies have shown that VirB8 contains an immunoreactive periplasmic domain (44) . In fact, treatment of the membranes with 5 M urea solubilizes VirB5 and VirB8, indicating that these proteins are peripherally associated with the membrane (16) . On the basis of these findings, the T-complex transport apparatus can be depicted as a complex of VirB proteins consisting of VirB4 and VirB11 ATPases localized at the cytoplasmic face of the cytoplasmic membrane; VirB6, a multispanning cytoplasmic membrane protein; and VirB5, VirB7, VirB8, VirB9, and VirB10 positioned predominantly or exclusively within the periplasmic space, possibly as a structure extending from the cytoplasmic membrane to the outer membrane (15) . VirB1, VirB2, and VirB3 may also localize in the periplasmic space or at the cell exterior and possibly are assembled as a pilus structure (23) .
Recently, genetic and biochemical approaches have been directed toward identifying specific interactions among the VirB proteins. For example, in vivo chemical cross-linking studies revealed that the ϳ48-kDa VirB10 protein cross-links to form homo-or heterooligomers with sizes of ϳ80, ϳ115, and ϳ140 kDa (48) . Interestingly, while oligomerization depends on the presence of VirB9, anti-VirB9 antiserum does not react with these high-molecular-weight complexes (3) . The VirB4 ATPase likely interacts with other VirB proteins, as can be deduced from the finding that VirB4 synthesis is required for the accumulation of VirB3 to wild-type levels (22) . In addition, merodiploids cosynthesizing wild-type VirB4 and ATP-binding-domain mutants exhibit reduced DNA transport efficiencies (5, 17) , consistent with the notion that VirB4 interacts with other components of the transport machinery. By contrast, merodiploids cosynthesizing wild-type VirB11 and ATP-binding-domain mutants exhibit wild-type transfer efficiencies (33, 41) . This observation led to speculation that VirB11 does not interact with the other components of the transport machinery (41), but we recently obtained evidence for an interaction between VirB11 and another Vir protein(s) through the identification of a VirB11 mutant with a 2-aminoacid substitution that resides outside of the ATP-binding domain and that renders merodiploids almost completely avirulent (33) .
Despite these advances, specific protein interactions among VirB proteins have not yet been demonstrated. In fact, there is no experimental evidence that the VirB proteins assemble together to form a single, multimeric T-complex transporterpilus. We initiated our characterization of this system by constructing a set of 11 mutants of octopine-type strain A348, each with a precise deletion of a virB gene (5, 6) . Immunoblot analyses revealed that the ⌬virB7 mutant possessed diminished steady-state levels of other VirB proteins, raising the possibility that VirB7 contributes to the stabilization of other VirB proteins during the assembly of the putative T-complex transport apparatus (6) . In the accompanying article, we biochemically confirmed sequence predictions that VirB7 is processed by signal peptidase II and that the invariant Cys-15 residue located within the signal peptidase II recognition site is fatty acylated. Results of localization studies indicated that the amino terminus of VirB7 anchors the lipoprotein predominantly but not exclusively to the outer membrane and that the hydrophilic carboxyl terminus of the protein resides within the periplasmic space (15) . In the present investigation, we examined the contribution of the VirB7 lipoprotein to the stabilization of other VirB proteins. Our findings support a model in which VirB7, in conjunction with VirB9, plays a critical role in stabilizing other VirB proteins during the biogenesis of the T-complex transport apparatus.
MATERIALS AND METHODS
Bacterial strains and growth conditions. A. tumefaciens A348 is a derivative of A136 that contains the octopine-type plasmid pTiA6NC (18) . Strain PC1000 is an A348 derivative that sustains a precise deletion of the virB operon (15) . Strains PC1007, PC1008, and PC1009 are A348 derivatives that sustain precise deletions of virB7, virB8, and virB9, respectively (6). 243Mx is a derivative of A348 that sustains a Tn3-HoHo1 insertion in virB1 (40) . Bacterial growth conditions have been described previously (9) . In A. tumefaciens and E. coli, plasmids were maintained by the addition of carbenicillin (50 g/ml), kanamycin (50 g/ml), or tetracycline (5 g/ml) to the growth medium.
Plasmid constructions. The following virB expression plasmids with IncP replication origins have been previously described: pPCB975 (P lac ::virB7 virB8) (6), pPCB985 (P virB ::virB8) (6), pPCB992 (P lac ::virB9) (6), and pED9 (P virB ::virB9 virB10 virB11) (47) . Plasmids pPCB873 (Crb r ) and pPCB875 (Kan r ) each express the virB7 derivative virB7::phoA41 from P lac (15) . The following plasmids express the corresponding virB::phoA fusions from P lac as previously described (15): pPCB813 (virB1::phoA164), pPCB824 (virB2::phoA121), pPCB833 (virB3:: phoA47), pPCB853 (virB5::phoA93), pPCB883 (virB8::phoA72), pPCB894 (virB9:: phoA74), and pPCB8103 (virB10::phoA276). To permit the controlled expression of virB7 and virB8 from P lac in A. tumefaciens, an HindIII fragment containing lacI q from pMMB22 (2) was treated with Klenow fragment of DNA polymerase I to make blunt ends and then was introduced into the unique ScaI site of pPC975. The resulting plasmid, pPC976, was digested with KpnI and ligated to similarly digested pSW172 (7), giving rise to pPCB976. Plasmid pPC976 digested with KpnI was treated with Klenow fragment to generate blunt ends and then was ligated to pED9 at the unique StuI site. The resulting plasmid, pPCB115, expresses virB7 and virB8 from P lac and virB9, virB10, and virB11 from P virB . Plasmid pPCB995 digested with PstI was treated with T4 DNA polymerase to generate blunt ends and then was ligated to pPC976 at the NruI site at bp 6521 as defined by Ward et al. (45, 46) . The resulting plasmid, pPCB970, expresses virB7 from P lac and virB9 from P virB .
Protein analysis and immunoblotting. Proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) as previously described (10) . For the visualization of low-molecular-weight proteins, a Tricine-SDS-polyacrylamide gel system was used (35) . Vir proteins were visualized by SDS-PAGE, protein transfer to nitrocellulose membranes, and immunoblot development with goat anti-rabbit antibodies conjugated to alkaline phosphatase (10) . Polyclonal antiserum specificities were previously documented for the VirE2 (10), VirB4 (47), VirB5 (5), VirB7 (15), VirB8 (15), VirB9 (47), VirB10 (47) , and VirB11 (9) proteins. For the induction of vir genes and comparisons of the steady-state levels of VirB proteins, cells routinely were grown to an optical density at 600 nm of 0.5 in MG/L medium (18) For an analysis of Vir protein content, 1 ml of culture adjusted to an optical density at 600 nm of 0.5 was pelleted by centrifugation, resuspended in 50 l of H 2 O and 50 l of protein sample buffer, and immediately boiled for 3 min. Protein loading on SDS-polyacrylamide gels routinely was normalized with respect to total protein content and, where indicated, VirE2 protein abundance to ensure that the vir genes were induced equivalently in all strains (6) . Immunoblots were scanned with a scanning densitometry system from PDI, Inc. (Huntington Station, N.Y.).
␤-Galactosidase activity assays. ␤-Galactosidase activity was quantitated by measuring the production of o-nitrophenol from o-nitrophenyl-␤-D-galactoside as described by Miller (29) .
Virulence assays. Virulence assays were performed by inoculating wound sites on Kalanchoe daigremontiana leaves as previously described (5, 6) . Virulence was scored in terms of tumor size and the time course of appearance, and photographs were taken 5 to 6 weeks after the inoculation. Virulence assays were repeated at least four times with leaves of different plants, and tumor formation was monitored for up to 6 months.
RESULTS

Contribution of VirB7 to the accumulation of other VirB proteins.
In preliminary studies, we determined that a precise deletion of the virB7 coding sequence from pTiA6NC causes a reduction in the steady-state levels of several VirB proteins, including VirB4, VirB9, VirB10, and VirB11 (6) . With the availability of additional anti-VirB antisera, we extended this analysis to examine the effect of the ⌬virB7 mutation on the steady-state levels of other VirB proteins. Next, with a goal of testing for a possible correlation between VirB7 synthesis and the accumulation of other VirB proteins, we examined the effect of expressing virB7 in trans on the steady-state levels of VirB proteins in strain PC1007. Using a similar approach and the corresponding ⌬virB8 and ⌬virB9 mutants, PC1008 and PC1009, respectively, we also tested for the importance of VirB8 and VirB9 synthesis for the accumulation of VirB proteins to abundant levels. Figure 1 shows a series of immunoblots that, with the exceptions noted, are representative of the results obtained in several repetitions of these experiments.
PC1007 cells failed to accumulate detectable levels of VirB proteins VirB7, VirB8, and VirB9 (Fig. 1, lane 2) . In addition, these cells accumulated reduced levels of VirB5 and VirB11 compared with the levels in wild-type A348 cells (Fig. 1 , compare lanes 1 and 2). VirB4 and VirB10 appear to be absent from the PC1007 extracts, but other blots prepared with PC1007 extracts showed that these proteins were detectable at low levels (see reference 6). We conclude that the ⌬virB7 mutation causes a dramatic reduction in the steady-state levels of at least seven VirB proteins. A348 and PC1007 cells accumulated comparable levels of other Vir proteins, such as VirE2, demonstrating that the effect of the ⌬virB7 mutation was specific for VirB proteins.
To test for a correlation between VirB7 synthesis and the accumulation of VirB proteins, we examined the VirB protein content of PC1007 cells transformed with the virB7 expression plasmid, pPCB974 (6) . Figure 1 shows that PC1007(pPCB974) cells accumulated VirB7 at wild-type levels, demonstrating that pPCB974 efficiently expresses virB7 (lane 5). These cells accumulated VirB9 to as much as 40% of the wild-type levels and VirB4 and VirB10 to higher levels than were detected in untransformed PC1007 cells (Fig. 1 , compare lanes 2 and 5). However, these cells still failed to accumulate detectable levels of VirB8. The low level of VirB proteins in PC1007(pPCB974) cells likely accounts for our previous finding that these cells are avirulent (6) . By contrast, we previously determined that PC1007 (pPCB975) cells coexpressing virB7 and virB8 in trans incite tumor formation at wild-type levels (6). The immunoblot studies showed that PC1007(pPCB975) cells accumulated each of the seven VirB proteins examined in this study at ϳ70 to 100% of the wild-type levels (Fig. 1, lane 6) . Furthermore, PC1007 (pPCB985) cells expressing only virB8 in trans accumulated VirB8 at wild-type levels, but the levels of other VirB proteins remained low (Fig. 1, lane 7) . These studies establish that the trans coexpression of both virB7 and virB8 is essential for restoring VirB proteins to physiological levels in PC1007 cells. Furthermore, the absence of VirB8 in PC1007 extracts is likely attributable to the absence of virB8 expression in these cells. The virB8 coding sequence has been predicted to initiate either within (24, 38) or 7 bp downstream (45, 46) of virB7. Since the ⌬virB7 mutation consists of a precise deletion of virB7 that extends from the translational start site of virB7 to that of virB8 (6), the ⌬virB7 mutation probably resulted in the deletion of important virB8 translation signals. PC1007(pPCB975) cells accumulated VirB9 at ϳ70% of wild-type levels, raising the further possibility that the ⌬virB7 mutation also exerts a slight polar effect on the expression of virB9 (Fig. 1, lane 6) .
Results of these studies indicated that the synthesis of VirB7 and VirB8 is important for the accumulation of several VirB proteins, including VirB9, VirB10, and VirB11, to wild-type levels. We also tested for the ability of PC1007 cells to accumulate VirB9, VirB10, and VirB11 at enhanced levels after being transformed with plasmid pED9 (47) . IncP replicons have been reported to reside in A. tumefaciens at an approximately fivefold higher copy number than that for pTiA6NC (7, 47) . Plasmid pED9 efficiently expresses virB9, virB10, and virB11, as judged by its ability to restore virulence and accumulation of VirB9, VirB10, and VirB11 at wild-type levels when introduced into strains sustaining polar (47) or nonpolar (reference 6 and data not shown) mutations in virB9, virB10, and virB11. Figure 1 shows that PC1007(pED9) cells accumulated VirB9, VirB10, and VirB11 at levels no greater than were detected in PC1007 cells (compare lanes 2 and 8). Thus, cosynthesis of VirB7 and VirB8 is absolutely essential for the accumulation of VirB9, VirB10, and VirB11 at wild-type levels in the ⌬virB7 background.
Contribution of VirB8 to the accumulation of VirB proteins. To test directly whether VirB8 contributes to the accumulation of other VirB proteins, we assessed the effect of a virB8 gene deletion on the steady-state levels of other VirB proteins. Surprisingly, although PC1008 cells accumulated low levels of VirB4, these cells accumulated wild-type levels of other VirB proteins, including VirB5, VirB7, VirB9, VirB10, and VirB11 ( Fig. 1, lane 3 , and see reference 6). Introduction of the virB8 expression plasmid, pPCB985, into PC1008 cells resulted in a slight enhancement in the levels of VirB4 and did not influence the levels of VirB5, VirB7, VirB9, VirB10, and VirB11 (Fig. 1 , lane 9). Therefore, with the possible exception of VirB4, the precise deletion of the virB8 coding sequence had little effect on the ability of PC1008 cells to accumulate abundant levels of other VirB proteins.
Immunoblot studies of PC1009 and PC1009(pPCB992) cells provided further evidence that VirB8 is dispensable for the general accumulation of VirB proteins. PC1009, a ⌬virB9 mutant, possessed undetectable or low levels of VirB4, VirB5, and VirB8 through VirB11 (Fig. 1, lane 4 , and see reference 6). However, PC1009 transformed with the virB9 expression plasmid, pPCB992, possessed undetectable levels of VirB8, and yet these cells accumulated wild-type levels of other VirB proteins (Fig. 1, lane 10 ). This result was of interest, because we previously established that VirB8 is an essential virulence factor and, furthermore, that PC1009(pPCB992) cells exhibited a wild-type virulence phenotype (6) . Plasmid pPCB992 consists of virB9 and ϳ230 bp of the upstream sequence encoding the 3Ј end of virB8. Although it is formally possible that this region encodes a functional, carboxyl domain of VirB8, there are no identifiable translational start sites in this upstream sequence and the ЈvirB8 coding sequence is out of frame with respect to the upstream lacZ sequence from the pUC118 vector (see references 6 and 47). We considered an alternative possibility that a low level of VirB8 accumulates transiently upon AS induction. In an effort to visualize VirB8 in PC1009 and PC1009(pPCB992) cells, we induced cells with AS and then harvested aliquots of the culture at 4, 8, 12, 18 , and 24 h after the induction. Immunoblot studies revealed that VirB8 accumulated at detectable, albeit low levels in cells induced for 8 and 12 h and was undetectable in cells induced for 4, 18, or 24 h (data not shown). Taken together, our immunoblot studies of PC1008 and PC1009(pPCB992) cells indicate that VirB8 does not contribute directly to the accumulation of most of the VirB proteins to wild-type levels. Furthermore, VirB8 appears to be capable of functioning as a virulence factor, even when present at low levels.
Contribution of VirB9 to the accumulation of VirB proteins. Immunoblot studies of PC1009 (Fig. 1, lane 4) synthesis of VirB9, like that of VirB7, is essential for the accumulation of most VirB proteins to abundant levels. Interestingly, although PC1009 cells accumulated VirB4, VirB5, and VirB8 through VirB11 at undetectable or low levels, these cells accumulated VirB7 at abundant levels (Fig. 1, lane 4) . This outcome indicated that (i) VirB9 synthesis is not critical for the stabilization of VirB7 and that (ii) VirB7 synthesis in the absence of VirB9 fails to stabilize other VirB proteins. PC1009(pPCB992) cells accumulated abundant levels of most of the VirB proteins (Fig. 1, lane 10) , thus establishing a correlation between VirB9 synthesis and the accumulation of most of the VirB proteins.
Accumulation of VirB proteins in response to modulation of VirB7 and VirB8 synthesis in PC1007(pPCB976) cells. The results of the immunoblot studies of the various ⌬virB7, ⌬virB8, and ⌬virB9 derivatives led us to investigate whether VirB protein levels could be modulated in response to the regulated synthesis of VirB7 and VirB8. We cloned lacI q onto plasmid pPCB975 for the IPTG-dependent regulation of virB7 and virB8 from P lac and introduced the resulting plasmid, pPCB976, into PC1007 cells. PC1007(pPCB976) cells were incubated in IM containing 200 M AS for the induction of the vir genes encoded by pTiA6NC and different concentrations of IPTG for the induction of virB7 and virB8. Immunoblots showed that VirB7 and VirB8 could be detected in cells induced with Ն20 M IPTG and that steady-state levels of both proteins increased with apparent linearity in cells induced with IPTG at 20 M to 1 mM (Fig. 2 and data not shown). PC1007(pPCB976) cells induced with 1 mM IPTG possessed VirB7 at wild-type levels and VirB8 at ϳ75% of wild-type levels (Fig. 2) .
The immunoblots further showed that VirB4, VirB9, VirB10, and VirB11 levels increased in parallel with those of VirB7 and VirB8 (Fig. 2 ). VirB4 and VirB10 accumulated to low levels and VirB9 to undetectable levels in PC1007 (pPCB976) cells induced with 200 M AS and Յ20 M IPTG. Each of these VirB proteins increased in abundance in cells induced with IPTG at 50 M to 1 mM (Fig. 2 and data not shown). Each protein accumulated at or near wild-type levels in cells induced with 1 mM IPTG (Fig. 2) . Interestingly, in several repetitions of these experiments, VirB11 accumulated to higher levels in uninduced cells than in cells induced with 20 and 50 M IPTG. Levels then increased in cells induced with IPTG at 100 M to 1 mM. VirB5 protein content was not reproducibly altered by incubation of the cells in different concentrations of IPTG. The amount of VirB5 detected in the cell extracts of cultures induced with 1 mM IPTG shown in Fig.  2 was aberrantly low and not representative of results obtained in several repetitions of these analyses. Together, the results of these studies established that steady-state levels of VirB4, VirB9, VirB10, and VirB11 were modulated specifically in response to changes in the levels of VirB7 and VirB8.
Accumulation of VirB9, VirB10, and VirB11 in response to modulation of VirB7 levels in PC1000(pPCB115) cells. We next tested whether VirB9, VirB10, and VirB11 also exhibited a dependence on VirB7 and VirB8 after these proteins were synthesized in strain PC1000, an A348 derivative sustaining a deletion of the virB operon (15) . We ligated pPCB976 to pED9 to yield pPCB115, an IncP plasmid that expresses virB9, virB10, and virB11 from P virB upon induction with AS and virB7 and virB8 from P lac upon induction with IPTG. Strain PC1000 (pPCB115) was induced with 50 M AS and IPTG at a range of concentrations. Immunoblot studies of PC1000(pPCB115) cells again revealed that VirB7 increased in abundance upon induction with increasing concentrations of IPTG; however, these cells failed to accumulate detectable levels of VirB8 regardless of the concentration of IPTG used for the induction of P lac (Fig. 3) .
The immunoblots further showed that VirB9, VirB10, and VirB11 levels increased in parallel with VirB7 protein content even in the apparent absence of VirB8 (Fig. 3 ). VirB9 and VirB10 accumulated to low levels in PC1000(pPCB115) cells induced with 50 M AS and Յ100 M IPTG. Both proteins increased in abundance in cells induced with IPTG at 100 M to 1 mM. However, in fully induced cells, VirB9 protein content was only ϳ50% and VirB10 protein content was only ϳ15% of wild-type levels. VirB11 exhibited the same profile as that observed with PC1007(pPCB976) cells in that it accumulated to higher levels in uninduced cells than in cells induced with 20 and 50 M IPTG and increased in abundance in cells
on December 18, 2017 by guest http://jb.asm.org/ induced with IPTG at 100 M to 1 mM (Fig. 3 and data not shown). Together, these studies established that a subset of VirB proteins, including VirB9, VirB10, and VirB11, accumulated in rough proportion to the amount of VirB7 independently of other VirB proteins. VirB7-dependent accumulation of monomeric VirB9 and a presumptive VirB7-VirB9 covalent heterodimer. During the course of our investigations, it became strikingly evident that the accumulation of VirB9 was strongly correlated with the synthesis of VirB7. To gain evidence for a direct interaction between these proteins, we tested whether VirB9 protein content could be modulated by altering the levels of VirB7 in the absence of other VirB proteins. We ligated pPCB976 to pED9 so that the expression of virB8 as well as that of virB10 and virB11 was disrupted (see Materials and Methods). The resulting IncP plasmid, pPCB970, expresses virB9 from P virB upon induction with AS and virB7 from P lac upon induction with IPTG. PC1000 cells carrying pPCB970 were induced with AS and IPTG at a range of concentrations. Figure 4A shows that cells induced with 50 M AS did not accumulate detectable levels of VirB7 or VirB9. Conversely, cells induced with 1 mM IPTG accumulated abundant levels of VirB7 but no detectable VirB9 (data not shown). Cells induced with both AS and IPTG accumulated both VirB7 and VirB9 in proportion to the amount of IPTG used for induction (Fig. 4A ). These findings established that VirB9 accumulated specifically in response to the synthesis of VirB7 in the absence of other VirB proteins.
In these studies, total cellular proteins were electrophoresed through SDS-polyacrylamide gels under reducing conditions. In a parallel analysis, total cellular proteins were suspended in protein sample buffer without ␤-mercaptoethanol and electrophoresed through SDS-polyacrylamide gels (Fig. 4B to D) . Under these electrophoresis conditions, the monomeric forms of VirB7 (4.5 kDa) and VirB9 (32 kDa) were undetectable even in cells fully induced for the expression of both virB7 and virB9 (Fig. 4B to D) . Instead, a species cross-reactive with both anti-VirB7 and anti-VirB9 antisera was detected at a position corresponding to ϳ36 kDa, the sum of the molecular sizes of VirB7 and VirB9 (Fig. 4C and D) . This species, designated complex C1, increased in abundance in cells induced with IPTG at increasing concentrations (Fig. 4B to D) . These properties strongly suggest that complex C1 consists of a VirB7-VirB9 heterodimer and, furthermore, that the heterodimer is dissociated upon exposure to reducing agents. We also detected a second, less abundant species that cross-reacted with both the VirB7 and VirB9 antisera and migrated as a doublet at a position corresponding to ϳ20 kDa (Fig. 4B to D) . This species, designated complex C2, also accumulated as a function of VirB7 synthesis.
Effect of a VirB7 derivative, VirB7::PhoA41, on steady-state levels of VirB proteins. A348(pPCB873) cells constitutively expressing virB7::phoA41 from P lac display the unusual property of accumulating to high levels only upon AS induction (15) . While the mechanism responsible for AS-dependent accumulation of VirB7::PhoA41 remains to be identified, we further discovered that AS-induced A348(pPCB873) cells also accumulate aberrantly low levels of VirB proteins. Figure 5 shows that these cells reproducibly accumulated VirB4, VirB5, and VirB7 through VirB11 at 10 to 30% of wild-type levels. VirB10 (48 kDa) was immunologically detectable as a faint band located immediately below the VirB7::PhoA41 (51-kDa) fusion protein. AS-induced A348(pPCB873) cells accumulated wild-type levels of other Vir proteins, e.g., VirE2 (Fig. 5) . A348(pPCB873) cells reproducibly incited the formation of no tumors or very small tumors compared with the tumors incited by wild-type A348 (Fig. 6) . By contrast, all other A348 merodiploids expressing other virB::phoA chimeric genes generated in this laboratory (15) accumulated wild-type levels of the VirB   FIG. 4 . Accumulation of VirB proteins in PC1000(pPCB970) cells. Cells were induced for virB9 gene expression with AS and for virB7 expression with IPTG at concentrations of 0, 20, 100, 500, and 1,000 M, as described in the text. Equivalent amounts of total cellular proteins were separated by glycine-SDS-PAGE and examined for VirB7 and VirB9 protein contents by immunostaining. Lanes A348 are total protein extracts from wild-type strain A348 suspended in ␤-mercaptoethanol-containing protein sample buffer to mark the positions of the VirB7 and VirB9 monomers. Lanes containing A348 extracts were separated from lanes containing PC1000(pPCB790) extracts to prevent the reduction of material in PC1000(pPCB970) extracts by the diffusion of ␤-mercaptoethanol. proteins (data not shown), and most exhibited wild-type virulence (Fig. 6) . Interestingly, A348 merodiploids expressing chimeric gene virB5::phoA93 or virB8::phoA72 reproducibly exhibited attenuated virulence phenotypes (Fig. 6) .
We considered the possibility that VirB7::PhoA41 represses transcription from the virB promoter. To test for such an activity, we introduced pPCB875 into strain 243Mx, a Tn3-HoHo1 derivative of A348 carrying lacZ fused to virB1, and monitored transcription from P virB by assaying for ␤-galactosidase activity. Both 243Mx and 243Mx(pPCB875) exhibited comparable levels of ␤-galactosidase activities, showing that the synthesis of VirB7::PhoA41 has no effect on transcription from P virB (data not shown). Similar studies using Tn3-HoHo1 mutants with lacZ fusions at the 5Ј ends of the virC, virD, and virE operons established that VirB7::PhoA41 also has no effect on transcription from promoters for these operons (15) . For reasons outlined below, we postulate that VirB7::PhoA41 interferes directly with the assembly of a stabilized complex of VirB proteins.
DISCUSSION
The distinctive property of almost all bacterial lipoproteins is that they are anchored at their lipid-modified, amino-terminal Cys residues to the membrane. This property makes them excellent candidates for functioning as stabilizing elements during the biogenesis of macromolecular surface structures. In this paper, we have presented several lines of evidence that VirB7, as a heterodimer with VirB9, promotes the assembly of a functional T-complex transport system. VirB7 and VirB9 contribute to assembly of a stabilized complex of VirB proteins. Our initial immunoblot studies of PC1007 cells showed that VirB7 synthesis is essential for the accumulation of several of the VirB proteins. However, as discussed in more detail below, we also found that VirB8 contributed to the stabilization of the presumed complex in the ⌬virB7 genetic background. The stabilizing effect of VirB7 and VirB8 was evident for VirB4, VirB5, VirB9, VirB10, and VirB11, as was shown by the ability of the virB7 and virB8 coexpression plasmid to restore these proteins to wild-type levels in the ⌬virB7 mutant and, furthermore, by the failure of virB9, virB10, and virB11 expression in trans to enhance the levels of these proteins in the absence of virB7 and virB8 expression. To further establish the correlation between VirB7 and VirB8 synthesis and the accumulation of other VirB proteins, we modulated the expression levels of virB7 and virB8 under conditions in which other virB genes were constitutively expressed (Fig. 2) . A similar approach led to the discovery of a stabilizing activity of SecF on the SecD and SecY components of the protein translocation machinery of E. coli (34) . With PC1007(pPCB976) cells, we showed that each of the VirB proteins for which we have antibodies increased in abundance in rough proportion to the amount of VirB7 and VirB8. With another PC1007 derivative expressing only virB7 from a regulatable P lac , we demonstrated that levels of VirB4, VirB9, and VirB10 accumulated specifically as a function of VirB7 synthesis (data not shown). However, as with PC1007 (pPCB974) cells (Fig. 1) , VirB4, VirB9, and VirB10 still accumulated to low levels even after these cells expressed virB7 at maximum levels.
We applied the general strategy of testing for a stabilizing effect of one protein on another protein(s) by expressing the corresponding genes from independently regulatable promoters to show that the accumulation of VirB9, VirB10, and VirB11 was strongly dependent on VirB7 synthesis even in the absence of other VirB proteins (Fig. 3) . Our inability to detect VirB8 in extracts of PC1000(pPCB115) cells has two implications. First, one or more of the VirB proteins missing in these cells contribute to the stabilization of VirB8. Second, VirB8 is at least dispensable for the assembly of a partially stabilized complex consisting of VirB7, VirB9, VirB10, and VirB11. That most of these proteins failed to accumulate to wild-type levels in fully induced cells can almost certainly be attributed to the absence of other VirB protein components required for the assembly of a fully stabilized transport apparatus. Even so, we argue that our ability to modulate levels of VirB9, VirB10, and VirB11 specifically in response to the regulated synthesis of VirB7 provides compelling evidence that these four proteins interact directly with each other. Even the observed inverse correlation between VirB7 synthesis and VirB11 accumulation in cells induced with IPTG at low concentrations (Fig. 3) is suggestive of some type of an interaction between these proteins. Perhaps the formation of a partial complex of VirB proteins is more destabilizing for VirB11 than is an unassembled or fully assembled complex. Given the probable localization of VirB7 in the periplasmic space and of VirB11 at the cytoplasmic face of the cytoplasmic membrane (15), stabilization of VirB11 is likely mediated through a cytoplasmicmembrane-spanning VirB protein such as VirB10.
The third use of this general strategy involved expressing virB7 and virB9 from independently regulatable promoters in the absence of other virB genes (Fig. 4) . The observed correlation between VirB7 synthesis and VirB9 accumulation in PC1000(pPCB970) is suggestive of a direct interaction between these proteins, but it was still possible that a protein other than one of the VirB proteins promoted the formation or stabilization of the proposed VirB7-VirB9 complex. We obtained evidence that VirB7 associates directly with VirB9 by the electrophoresis of PC1000(pPCB970) extracts under nonreducing conditions. Three properties of complex C1 visualized in these gels strongly suggest that it is a VirB7-VirB9 heterodimer: (i) migration as a 36-kDa species, (ii) reactivity FIG. 6 . Virulence of A348 merodiploids synthesizing wild-type VirB proteins from the native virB operon and VirB::PhoA fusion proteins from virB::phoA expression plasmids. Wound sites of Kalanchoe daigremontiana were inoculated with ϳ10
8 CFU of A348 carrying the plasmids shown (see Materials and Methods) and photographed after 5 weeks. Wound sites also were inoculated with PC1007(pXZB16), which synthesizes VirB7C15S, and PC1007(pXZB17), which synthesizes VirB7C15S::PhoA41, to examine the ability of these VirB7 derivatives to function as virulence factors (see reference 15).
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on December 18, 2017 by guest http://jb.asm.org/ with both the anti-VirB7 and anti-VirB9 antisera, and (iii) accumulation in proportion to the amount of VirB7 synthesis (Fig. 4) . Recently, as an extension of the present study, we confirmed that VirB7 interacts with VirB9 via the formation of an intermolecular disulfide bridge between reactive residues Cys-24 of VirB7 and Cys-262 of VirB9 (39) . The doublet of bands designated complex C2 may also contain VirB7 and VirB9, since it also cross-reacted with both antisera and increased in abundance as a function of VirB7 synthesis. However, its migration as an ϳ20-kDa species suggests that complex C2 either is a different form of the VirB7-VirB9 heterodimer, possibly one that possesses intramolecular crosslinks, or represents a proteolytic breakdown product of the heterodimer. A third possibility currently under investigation is that complex C2 consists of VirB7 linked to another protein(s) that reacts with the anti-VirB9 antiserum. In addition to providing evidence for a covalent interaction between VirB7 and VirB9, results of our studies of PC1000(pPCB970) clearly showed that the accumulation of VirB9 is strictly dependent on the synthesis of VirB7. This dependence accounts for the absence of VirB9 in all the strains examined in these studies that are devoid of VirB7 synthesis. Taken together with the further observation that accumulation of VirB9 is essential for the accumulation of other VirB proteins to wild-type levels ( Fig. 1) , we suggest that the principal, perhaps exclusive, function of VirB7 is to stabilize VirB9. In turn, we predict that VirB9, or perhaps more accurately VirB9 in the context of the VirB7-VirB9 heterodimer, establishes interactions with other VirB proteins that are critical for the further assembly of a stabilized T-complex transporter.
Role of VirB8? The contribution of VirB8 to the assembly or function of the T-complex transporter remains to be clarified. Results of the immunoblot studies of PC1007 derivatives suggest that VirB8 somehow contributes to the stabilization of VirB proteins, possibly through an interaction with VirB7. It is interesting to note that the virB7, virB8, and virB9 coding sequences overlap or are in close juxtaposition, suggestive of translational coupling which could serve to ensure the cosynthesis of interactive proteins. Given our demonstration of dimer formation between VirB7 and VirB9 (39), it is conceivable that VirB8 promotes the assembly or stabilization of this dimer, possibly by facilitating the correct alignment of reactive Cys residues during the folding of both polypeptides.
The apparent contribution of VirB8 to the stabilization of VirB proteins in PC1007 cells, however, must be reconciled with the finding that VirB7 and VirB9 (Fig. 1) , the VirB7-VirB9 heterodimer (data not shown), and most other VirB proteins (Fig. 1) accumulate to wild-type levels in PC1008 cells. At present, we can only speculate that a polar effect of the ⌬virB7 mutation or other effects of the mutation such as the localized destabilization of mRNA interfere with the synthesis of several VirB proteins and, hence, their accumulation to levels required for assembly into a stabilized structure. Synthesis of abundant levels of VirB7 and VirB8 from pPCB975 may somehow compensate for a loss of coordinated VirB protein synthesis in PC1007 cells. Of possible significance is that PC1007(pPCB975) cells constitutively synthesize VirB7 and VirB8 from P lac , which could mean that a pool of both proteins is available for interacting with and stabilizing newly synthesized VirB proteins during transporter biogenesis. Alternatively, our studies to date do not exclude the possibility that sequences within the virB8 gene alter the efficiency of virB7 expression from P lac on pPCB975, for example, by stabilizing (or destabilizing) the message or by modulating translational efficiency. As was amply demonstrated in this study, modulation of VirB7 protein synthesis has profound effects on the accumulation of other VirB proteins.
Interestingly, our immunoblot studies revealed that VirB8 accumulates to low levels within a brief period following AS induction of PC1009 and PC1009(pPCB992) cells. This finding, coupled with the previous observation that PC1009(pPCB992) cells exhibit wild-type virulence (6) , raises the intriguing possibility that VirB8 is not a structural component of the transport apparatus in wild-type cells but rather contributes a catalytic function required for transporter biogenesis or activity. Similarly, A348 derivatives synthesizing low levels of VirB4 were shown to exhibit wild-type virulence, prompting speculation that VirB4 contributes a recycling activity required for transporter biogenesis (17) . Mechanistically, VirB4 and VirB8 probably contribute distinct functions, given the fact that VirB4 is an ATPase associated at the cytoplasmic face of the cytoplasmic membrane (5, 12) and VirB8 resides predominantly or exclusively within the periplasmic space (15, 44) . Nevertheless, it is notable that PC1008 cells accumulate wildtype levels of most VirB proteins and low levels of VirB4 and that the trans expression of virB8 in these cells enhances the steady-state levels of VirB4 ( Fig. 1) 
(6).
VirB7::PhoA41 arrests assembly of a VirB protein complex. Studies of dominant mutant alleles can provide important information about the domains of the encoded proteins required for function and for making contact with other molecules (21) . We have identified three phenotypes associated with the constitutive expression of virB7::phoA41. First, the corresponding product, VirB7::PhoA41, accumulates to high levels upon AS induction only in strains possessing a functional VirA-VirGdependent transduction system responsible for vir gene activation (15) . Potentially, VirA and VirG direct the synthesis of a factor that forms a stabilizing interaction with the fusion protein; the identification of such a factor ultimately could provide important information about the protein contacts required for stabilizing native VirB7 (15) . Second, synthesis of VirB7:: PhoA41 causes a corresponding reduction in the steady-state levels of all VirB proteins examined (Fig. 5) . Finally, synthesis of VirB7::PhoA41 causes a severely attenuated virulence phenotype (Fig. 6 ). The dominance of virB7::phoA41 is reminiscent of that of recently identified alleles of SecY whose products were proposed to prevent the formation of a functional protein translocation complex in E. coli. Several of these dominant negative alleles encoded SecY::PhoA variants, and mapping of the SecY-PhoA fusion junctions led to the assignment of a region of SecY likely to be involved in the interaction with other components of the translocation machinery (36) .
Accordingly, the dominance of virB7::phoA41 is suggestive evidence that a site(s) responsible for interacting with another VirB protein(s) resides near the amino terminus of VirB7. Recently, we made three key discoveries that support this interpretation and that also might explain how VirB7::PhoA41 synthesis disrupts the assembly of a stabilized complex of VirB proteins. First, we demonstrated that native VirB7 is stabilized by the formation of disulfide-cross-linked homodimers via a reactive Cys-24 residue (39) . Second, we determined that VirB7::PhoA41 forms disulfide-cross-linked dimers both with itself and with native VirB7 via Cys-24 (39) . Finally, as mentioned above, we demonstrated that VirB7 stabilizes VirB9 by the formation of disulfide-cross-linked heterodimers via the Cys-24 and Cys-262 residues, respectively (39) . On the basis of these findings, we suggest that VirB7::PhoA41 forms nonproductive dimers with VirB7 and that this interaction prevents VirB7 from forming dimers with and stabilizing VirB9. If this scenario is correct, VirB7::PhoA41 synthesis imposes a block at a very early stage in the biogenesis of a functional T-complex transport apparatus, namely, the formation of the VirB7-VirB9 heterodimer (see below).
The discovery of a VirB7 derivative with dominant effects with respect to the accumulation of VirB proteins and virulence is significant, because it provides the first experimental evidence that at least seven of the VirB proteins, VirB4, VirB5, and VirB7 through VirB11, assemble into a single, multimeric complex required for T-complex transport. Furthermore, this discovery clearly establishes VirB7 as a critical component of this complex.
VirB7 and VirB9 coordinate biogenesis of a functional Tcomplex transport apparatus: implications for other macromolecular transporters. The data presented in this paper provide compelling evidence that VirB7 and VirB9 play essential roles in stabilizing a complex of VirB proteins. Taken together with our discovery that these proteins interact via an intermolecular disulfide bond (39), our findings lead us to propose that the T-complex transport apparatus is assembled according to the following sequence of events. Newly synthesized VirB7 is exported via the general export pathway, its signal sequence is cleaved by signal peptidase II, and Cys-15, which constitutes the amino terminus of the processed protein, is fatty acylated. We have biochemically confirmed the latter two steps of this maturation pathway (15) ; export via the Sec protein translocation machinery is inferred from export studies of Lpp, the major outer membrane lipoprotein of E. coli, and the bacteriocin release lipoproteins (see references 20 and 32), small lipoproteins that are responsible for colicin secretion and that have been shown to bear sequence similarities with VirB7 (38) . VirB7 then dimerizes with itself and with VirB9 (39), most probably during the folding of the newly secreted polypeptides, although dimerization also could occur concomitantly with the sorting of these proteins to the outer membrane. We postulate that the sorting of the VirB7 dimers is mediated by a carrier protein analogous to that recently shown to be responsible for the delivery of Lpp to a presumptive outer membrane receptor (8, 27) . In the next step of the biosynthetic pathway, we suggest that the VirB7-VirB9 dimer functions as a nucleation center for the assembly of a stabilized complex of VirB proteins that constitutes the T-complex transport apparatus. So far, our studies support events in the proposed assembly pathway that follow the positioning of VirB7. Earlier events, such as the export, sorting, and/or stabilization of VirB7, likely require housekeeping functions, i.e., those provided by Sec proteins and periplasmic oxidoreductases as well as other Vir proteins, possibly one or more VirB proteins coded for by genes residing upstream of virB7 in the virB operon. Events following the assembly of the proposed VirB7-VirB9 nucleation center also are largely uncharacterized, although the results of our studies lead to predictions that VirB9 interacts with and stabilizes VirB10 and VirB11. Clearly, this proposed scheme highlights the importance of further investigations into the nature of interactions between VirB9 and other VirB proteins.
Are other macromolecular surface structures assembled according to this proposed pathway? Indeed, many macromolecular structures have been shown to possess lipoprotein components. Among the evolutionarily related systems, the Tra operon of the IncN plasmid, pKM101, encodes a VirB7 homolog (31) , and the Tra2 operon of the IncP␣ plasmid, RP4, although missing a VirB7 homolog, encodes two lipoproteins, TrbH and TrbK, that could provide stabilizing functions analogous to those proposed for VirB7 (19, 25) . Recent studies of the Bordetella pertussis ptl operon have located an orf between the ptlD and ptlE genes with the potential of encoding a 61-residue mature lipoprotein (49, 50) . In addition, many dedicated protein export systems unrelated to the T-complex transporter also possess lipoprotein components. These include members of the type II secretion pathway, i.e., the Klebsiella oxytoca pullulanase and Erwinia carotovora pectate lyase secretion systems whose lipoprotein components are PulS and OutS, respectively (13, 32) , as well as members of the type III secretion pathway, i.e., the Yersinia enterocolitica Yop and Shigella flexneri Ipa secretion systems whose lipoprotein components are YscJ and MxiJ and MxiM, respectively (1, 28) . Finally, the paradigm of bacterial conjugative plasmids, E. coli F factor, encodes two lipoproteins, TraT (30) and TraV (14) . Of these, TraV has been proposed to provide an anchoring function for the recruitment of pilus-associated proteins to the outer membrane during pilus biogenesis (14) . As a group, these lipoproteins generally share only the signature signal peptidase II cleavage and lipid modification site as a common structural feature. However, their unique mode of membrane attachment, coupled with their widespread association with diverse membrane transport systems, makes it tempting to speculate that, like VirB7, these lipoproteins contribute essential stabilizing functions during transporter biogenesis.
